In early September 2024, a journalist’s journey to St. Bartholomew’s Hospital, London’s oldest medical institution, intertwines with a cutting-edge kidney cancer vaccine trial. The hospital, founded in 1123, balances medieval heritage with modern innovation, its North Wing undergoing restoration while housing a Phase 2 mRNA vaccine study. The journalist, diagnosed with a 5cm kidney tumor, navigates clinical uncertainty: a 272-person global trial led by Moderna, using personalized immunotherapy alongside checkpoint inhibitors.

Her story begins with a late-night hospital visit after detecting an incidentaloma, leading to surgery and a reclassification from Stage 1B to Stage 3 cancer. The trial’s dual approach—vaccine and immunotherapy—aims to boost immune response, though results remain blind. Half of participants receive placebo, leaving long-term outcomes uncertain.